Aggregate Processing Articles & Analysis
11 news found
About OLX-07010 OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders. ...
A study was conducted in the tau P301L JNPL3 mouse model for tau aggregation and motor impairment that was aged prior to treatment in order to study the therapeutic effect of OLX07010. Statistically significant results showed that treatment prevented further accumulation of tau aggregates and overall levels of tau in the mice over 5 months of treatment ...
About Oligomerix’s Lead Program Oligomerix’s lead clinical candidate is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process thought to be important in the development of Alzheimer’s disease and other neurodegenerative disorders. ...
” About OLX-07010 OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders. ...
About OLX-07010 OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders. ...
” Initial studies in two mouse models, representative of tau aggregation in Alzheimer’s (htau) and rare neurodegenerative diseases (P301L tau JNPL3), have shown that oral administration of OLX-07010 to young mice prevented the self-association of tau and the accumulation of large insoluble aggregates of tau associated with neurodegenerative diseases. ...
About Oligomerix’s Lead Program Oligomerix’s lead clinical candidate is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process thought to be important in the development of Alzheimer’s disease and other neurodegenerative disorders. ...
Professor Armin Giese, CSO of MODAG, continued, “Anle138b is a small molecule that specifically binds to toxic oligomeric structures of alpha-synuclein, the core aggregating protein in Parkinson's disease. This prevents the formation of new oligomers and thereby blocks the disease-specific aggregation process from advancing. ...
Anle138b is a small molecule compound that specifically binds toxic oligomeric structures of alpha-synuclein, the core aggregating protein in Parkinsonian disorders, preventing new oligomers from forming and blocking the aggregation process from advancing. ...
Sub-visible particle aggregates in biopharmaceuticals are an unintended consequence of the manufacturing process. ...
Benevity provides the back-end platform that facilitates donation processing, aggregation of micro-donations, distribution of funds and tax receipt capabilities. ...